Literature DB >> 21788538

Cardiovascular risk prediction in diabetic men and women using hemoglobin A1c vs diabetes as a high-risk equivalent.

Nina P Paynter1, Norman A Mazer, Aruna D Pradhan, J Michael Gaziano, Paul M Ridker, Nancy R Cook.   

Abstract

BACKGROUND: It is unclear whether models that include hemoglobin A(1c) (HbA(1c)) levels only for diabetic patients improve the ability to predict cardiovascular disease (CVD) risk compared with the currently recommended classification of diabetes as a cardiovascular risk equivalent.
METHODS: A total of 24 674 women (including 685 diabetic participants at baseline) and 11 280 men (including 563 diabetic participants at baseline) were followed up prospectively for cardiovascular disease (CVD). One hundred twenty-five CVD events occurred in diabetic women (666 in nondiabetic women), and 170 events occurred in diabetic men (1382 in nondiabetic men). Models for CVD risk were generated separately for men and women using the traditional CVD risk factors with the addition of a term for HbA(1c) levels only for diabetic individuals. In diabetic participants, the resulting predicted risks were compared with classification of diabetes as a cardiovascular risk equivalent (10-year CVD risk of at least 20%).
RESULTS: In women, the models including HbA(1c) levels in diabetic participants improved the C statistic by 0.177 (P < .001) over the risk equivalence model and showed improved reclassification (net reclassification improvement [NRI] of 26.7% [P = .001]). In men, the improvements were more modest but still statistically significant (C statistic change of 0.039 [P = .02]; NRI of 9.2% [P = .04]). Including HbA(1c) levels also improved prediction over a dichotomous term for diabetes in women (NRI of 11.8% [P = .03]) but not in men.
CONCLUSIONS: In both women and men with diabetes at baseline, we observed significant improvements in predictive ability of CVD risk using models incorporating HbA(1c) levels compared with classification of diabetes as a cardiovascular risk equivalent.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21788538      PMCID: PMC3202025          DOI: 10.1001/archinternmed.2011.351

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  26 in total

1.  Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation.

Authors:  Michael Pignone; Mark J Alberts; John A Colwell; Mary Cushman; Silvio E Inzucchi; Debabrata Mukherjee; Robert S Rosenson; Craig D Williams; Peter W Wilson; M Sue Kirkman
Journal:  Circulation       Date:  2010-05-27       Impact factor: 29.690

2.  Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus.

Authors:  Justin W Timbie; Rodney A Hayward; Sandeep Vijan
Journal:  Arch Intern Med       Date:  2010-06-28

3.  A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women.

Authors:  J E Manson; G A Colditz; M J Stampfer; W C Willett; A S Krolewski; B Rosner; R A Arky; F E Speizer; C H Hennekens
Journal:  Arch Intern Med       Date:  1991-06

4.  Use and misuse of the receiver operating characteristic curve in risk prediction.

Authors:  Nancy R Cook
Journal:  Circulation       Date:  2007-02-20       Impact factor: 29.690

5.  Physical activity and risk for cardiovascular events in diabetic women.

Authors:  F B Hu; M J Stampfer; C Solomon; S Liu; G A Colditz; F E Speizer; W C Willett; J E Manson
Journal:  Ann Intern Med       Date:  2001-01-16       Impact factor: 25.391

6.  A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Authors:  Paul M Ridker; Nancy R Cook; I-Min Lee; David Gordon; J Michael Gaziano; Joann E Manson; Charles H Hennekens; Julie E Buring
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

7.  Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial.

Authors:  Howard D Sesso; Julie E Buring; William G Christen; Tobias Kurth; Charlene Belanger; Jean MacFadyen; Vadim Bubes; JoAnn E Manson; Robert J Glynn; J Michael Gaziano
Journal:  JAMA       Date:  2008-11-09       Impact factor: 56.272

8.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.

Authors:  N Sarwar; P Gao; S R Kondapally Seshasai; R Gobin; S Kaptoge; E Di Angelantonio; E Ingelsson; D A Lawlor; E Selvin; M Stampfer; C D A Stehouwer; S Lewington; L Pennells; A Thompson; N Sattar; I R White; K K Ray; J Danesh
Journal:  Lancet       Date:  2010-06-26       Impact factor: 202.731

9.  Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures.

Authors:  Nancy R Cook; Paul M Ridker
Journal:  Ann Intern Med       Date:  2009-06-02       Impact factor: 25.391

10.  Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study.

Authors:  Anette E Buyken; Arnold von Eckardstein; Helmut Schulte; Paul Cullen; Gerd Assmann
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2007-04
View more
  17 in total

1.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson; Karen M Eddleman; Nicole M Jarrett; Ken LaBresh; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

2.  Risk prediction of major complications in individuals with diabetes: the Atherosclerosis Risk in Communities Study.

Authors:  C M Parrinello; K Matsushita; M Woodward; L E Wagenknecht; J Coresh; E Selvin
Journal:  Diabetes Obes Metab       Date:  2016-06-14       Impact factor: 6.577

3.  Contributors to mortality in high-risk diabetic patients in the Diabetes Heart Study.

Authors:  Amanda J Cox; Fang-Chi Hsu; Barry I Freedman; David M Herrington; Michael H Criqui; J Jeffrey Carr; Donald W Bowden
Journal:  Diabetes Care       Date:  2014-07-02       Impact factor: 19.112

4.  Is it AKI or nonrecovery of renal function that is important for long-term outcomes?

Authors:  Steven G Coca
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-10       Impact factor: 8.237

Review 5.  Metformin use among individuals at risk for type 2 diabetes.

Authors:  Lewis H Kuller
Journal:  Curr Diab Rep       Date:  2012-06       Impact factor: 4.810

Review 6.  Does AKI truly lead to CKD?

Authors:  Dena E Rifkin; Steven G Coca; Kamyar Kalantar-Zadeh
Journal:  J Am Soc Nephrol       Date:  2012-03-29       Impact factor: 10.121

7.  Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease.

Authors:  Helen Vlassara; Jaime Uribarri; Weijing Cai; Susan Goodman; Renata Pyzik; James Post; Fabrizio Grosjean; Mark Woodward; Gary E Striker
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-29       Impact factor: 8.237

Review 8.  Cardiovascular disease risk prediction in women: is there a role for novel biomarkers?

Authors:  Nina P Paynter; Brendan M Everett; Nancy R Cook
Journal:  Clin Chem       Date:  2013-10-07       Impact factor: 8.327

Review 9.  Atherosclerotic Cardiovascular Disease Risk and Evidence-based Management of Cholesterol.

Authors:  Satyajeet Roy
Journal:  N Am J Med Sci       Date:  2014-05

10.  Liver function tests and risk prediction of incident type 2 diabetes: evaluation in two independent cohorts.

Authors:  Ali Abbasi; Stephan J L Bakker; Eva Corpeleijn; Daphne L van der A; Ron T Gansevoort; Rijk O B Gans; Linda M Peelen; Yvonne T van der Schouw; Ronald P Stolk; Gerjan Navis; Annemieke M W Spijkerman; Joline W J Beulens
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.